Dopavision: Funding, Investors & Team (Sep 2026)
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.
Dopavision has raised $14.2M across 1 funding round on record, the most recent a Series A of $14.2M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Dopavision Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Dopavision Funding Rounds
Dopavision Founders and Leadership Team
No contact details are on record for this team yet.
Dopavision Funding Compared to Other Biotechnology Startups
Dopavision's latest round of $14.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Dopavision in Biotechnology and Berlin
Companies Similar to Dopavision
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Dopavision Funding FAQs
What does Dopavision do?
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.
How much funding has Dopavision raised?
Dopavision has raised $14.2M across 1 round on record. The most recent is a Series A of $14.2M announced in Jul 2021.
When did Dopavision last raise funding?
Dopavision's most recent funding round on record is a Series A of $14.2M, announced in Jul 2021.
Who is the CEO of Dopavision?
Hamed Bahmani is listed as CEO at Dopavision.
Where is Dopavision headquartered?
Dopavision is based in Berlin, Germany.
How many employees does Dopavision have?
Dopavision is in the 11-50 employee band.
How does Dopavision's funding compare to other Biotechnology startups?
Dopavision's latest round of $14.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Dopavision Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Dopavision is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.